CoviVac vaccination induces production of neutralizing antibodies against Delta and Omicron variants of SARS-CoV-2
CoviVac vaccination induces production of neutralizing antibodies against Delta and Omicron variants of SARS-CoV-2
Abstract Vaccines are proven to be an effective tool in prophylaxis of severe COVID-19, but emerging mutated SARS-CoV-2 variants constantly challenge vaccines’ protectivity. We have evaluated the ability of the sera from individuals vaccinated with two variants of inactivated vaccine CoviVac and COVID-19 convalescents (May-December 2020) to neutralize SARS-CoV-2 variants Delta and Omicron. Four groups of serum samples (CoviVac vaccinees; COVID-19 convalescents; mice immunized with CoviVac preparations based on prototype B.1.1 strain and Delta variant) were evaluated in virus neutralization test against SARS-CoV-2 heterologous B.1.1 virus, Delta and Omicron variants. CoviVac preparations based on B.1.1 and Delta induced neutralizing antibodies against SARS-CoV-2 B.1.1 and two variants of concern. We observed a decrease in neutralization capacity in the sera from CoviVac (based on B.1.1 strain) vaccinees: 57.1% samples had detectable neutralizing antibodies against Delta and 61.9% against Omicron variants. Sera samples of all (100%) mice immunized with a candidate vaccine based on the SARS-CoV-2 Delta variant strain had neutralizing antibodies against all tested strains.
Kozlovskaya Liubov、Piniaeva Anastasia、Kovpak Anastasia、Shishova Anna、Ishmukhametov Aydar、Kondrashova Alla、Gordeychuk Ilya、Lunin Aleksandr、Apolokhov Vasiliy、Shustova Elena、Fominykh Ksenia、Volok Viktor、Ivin Yuri、Tcelykh Irina、Siniugina Aleksandra
Chumakov FSC R&D IBP RAS (Institute of poliomyelitis)||Institute for Translational Medicine and Biotechnology, First Moscow State Medical University (Sechenov University)Chumakov FSC R&D IBP RAS (Institute of poliomyelitis)Chumakov FSC R&D IBP RAS (Institute of poliomyelitis)Chumakov FSC R&D IBP RAS (Institute of poliomyelitis)||Institute for Translational Medicine and Biotechnology, First Moscow State Medical University (Sechenov University)Chumakov FSC R&D IBP RAS (Institute of poliomyelitis)||Institute for Translational Medicine and Biotechnology, First Moscow State Medical University (Sechenov University)Chumakov FSC R&D IBP RAS (Institute of poliomyelitis)Chumakov FSC R&D IBP RAS (Institute of poliomyelitis)||Institute for Translational Medicine and Biotechnology, First Moscow State Medical University (Sechenov University)Chumakov FSC R&D IBP RAS (Institute of poliomyelitis)Chumakov FSC R&D IBP RAS (Institute of poliomyelitis)Chumakov FSC R&D IBP RAS (Institute of poliomyelitis)Chumakov FSC R&D IBP RAS (Institute of poliomyelitis)Chumakov FSC R&D IBP RAS (Institute of poliomyelitis)Chumakov FSC R&D IBP RAS (Institute of poliomyelitis)Chumakov FSC R&D IBP RAS (Institute of poliomyelitis)Chumakov FSC R&D IBP RAS (Institute of poliomyelitis)
预防医学生物科学现状、生物科学发展生物科学研究方法、生物科学研究技术
neutralizing antibodiesSARS-CoV-2Omicron variantDelta variantinactivated vaccine
Kozlovskaya Liubov,Piniaeva Anastasia,Kovpak Anastasia,Shishova Anna,Ishmukhametov Aydar,Kondrashova Alla,Gordeychuk Ilya,Lunin Aleksandr,Apolokhov Vasiliy,Shustova Elena,Fominykh Ksenia,Volok Viktor,Ivin Yuri,Tcelykh Irina,Siniugina Aleksandra.CoviVac vaccination induces production of neutralizing antibodies against Delta and Omicron variants of SARS-CoV-2[EB/OL].(2025-03-28)[2025-04-26].https://www.medrxiv.org/content/10.1101/2022.02.10.22270781.点此复制
评论